Brightgene Bio-medical - Public Comps and Valuation Multiples

Brightgene Bio-medical Overview

About Brightgene Bio-medical

Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.

Founded

2001

HQ

Employees

n/a

Website

bright-gene.com

Sectors

Drug Development & Therapeutics
Small Molecules
BioTech
DeepTech

Financials

Last FY Revenue $183M

Last FY EBITDA $45.9M

EV

$3.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Brightgene Bio-medical Financials

See Brightgene Bio-medical valuation multiples based on analyst estimates

Brightgene Bio-medical P&L

In the most recent fiscal year, Brightgene Bio-medical reported revenue of $183M and EBITDA of $45.9M.

Brightgene Bio-medical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Brightgene Bio-medical valuation multiples based on analyst estimates

	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	XXX	$183M	XXX	XXX	XXX
Gross Profit	XXX	$105M	XXX	XXX	XXX
Gross Margin	XXX	58%	XXX	XXX	XXX
EBITDA	XXX	$45.9M	XXX	XXX	XXX
EBITDA Margin	XXX	25%	XXX	XXX	XXX
EBIT	XXX	$35.8M	XXX	XXX	XXX
EBIT Margin	XXX	20%	XXX	XXX	XXX
Net Profit	XXX	$27.0M	XXX	XXX	XXX
Net Margin	XXX	15%	XXX	XXX	XXX
Net Debt	XXX	$131M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Brightgene Bio-medical including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Brightgene Bio-medical achieved $183M in revenue and $45.9M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	Analyst estimates available to subscribers	$183M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$105M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	57.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$45.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	25.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$35.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	19.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$27.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	14.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$131M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Brightgene Bio-medical

This financial data table provides comprehensive performance metrics for Brightgene Bio-medical, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Brightgene Bio-medical reported $183M in total revenue.
Fiscal year EBITDA was $45.9M.
The company maintained a gross profit margin of 57.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 25.0%.
Net profit margin reached 14.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Brightgene Bio-medical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Brightgene Bio-medical Stock Performance

Brightgene Bio-medical has current market cap of CNY 20.8B (or $3.0B), and EV of CNY 22.5B (or $3.2B).

Market Cap Evolution

Brightgene Bio-medical Stock Data

As of January 2, 2026, Brightgene Bio-medical's stock price is CNY 49 (or $7).

See Brightgene Bio-medical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.2B	$3.0B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Brightgene Bio-medical Valuation Multiples

Brightgene Bio-medical's trades at 17.5x EV/Revenue multiple, and 70.1x EV/EBITDA.

See valuation multiples for Brightgene Bio-medical and 15K+ public comps

Brightgene Bio-medical Financial Valuation Multiples

As of January 2, 2026, Brightgene Bio-medical has market cap of $3.0B and EV of $3.2B.

Equity research analysts estimate Brightgene Bio-medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Brightgene Bio-medical's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$3.0B	XXX	$3.0B	XXX	XXX	XXX
EV (current)	$3.2B	XXX	$3.2B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	17.5x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	70.1x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	89.7x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	109.7x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-1932.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Brightgene Bio-medical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Brightgene Bio-medical Margins & Growth Rates

Brightgene Bio-medical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Brightgene Bio-medical's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Brightgene Bio-medical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Brightgene Bio-medical and other 15K+ public comps

Brightgene Bio-medical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	23%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	38%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial